Stay updated on Nivolumab in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Nivolumab in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe study record for the NIVOREN Phase II trial of nivolumab in metastatic renal cell carcinoma is displayed, including its design, participant criteria, locations, and outcome measures. The record indicates the study is completed and is no longer recruiting.SummaryDifference51%

- Check19 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2. The study record is still unavailable on the page.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces an NIH website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check33 days agoChange DetectedThe site footer revision label changes from v3.7.1 to v3.7.2; the study record page continues to display a 403 error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedA 403 Forbidden page now displays for the study record, indicating access is blocked. A large portion of the trial's core metadata and related terms appears to have been removed, reducing the information available to readers.SummaryDifference18%

Stay in the know with updates to Nivolumab in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Metastatic Renal Cell Carcinoma Clinical Trial page.